Latent-Y: The Autonomous AI Agent for Drug Design at Scale

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Software
Research
Professional Services
Pharmaceutical
Data Management
Venture Capital
Technology
Artificial Intelligence
Health Technology
Science
Biotechnology
Health
Other Science
Latent-Y

More Like This

PR Newswire associated0

Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery

PR Newswire associated0

DeepL unveils autonomous AI agent for businesses

Overview of Research (Graphic: Business Wire)

A research paper on AI-driven drug discovery by SAKURA internet and COGNANO was accepted by NeurIPS 2024, a prestigious AI conference

PR Newswire associated0

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic

Business Wire logo

LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes

PR Newswire associated0

XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

PR Newswire associated0

Lynx Analytics Introduces Lumen, an Agentic AI Framework to Improve Decision-Making in Life Sciences